Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6600749.pdf
Reference38 articles.
1. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811–814
2. Aktepe F, Kapucuoglu N, Pak I (1996) The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer. Histopathology 29: 63–67
3. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 200–206
4. Bergh J (1999) Clinical studies of p53 in treatment and benefit of breast cancer patients. Endocr Relat Cancer 6: 51–59
5. Billgren AM, Rutqvist LE, Tani E, Wilking N, Fornander T, Skoog L (1999) Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival. Acta Oncol 38: 597–601
Cited by 234 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Assessment of Predictive Factors for Response to Neoadjuvant Chemotherapy in Breast Cancer;Asian Journal of Oncology;2023-12-17
2. Is Ki-67 Really Useful as a Predictor for Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer?;Indian Journal of Surgical Oncology;2023-09-29
3. Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients;2023-06-08
4. Estrogen receptor α confers Nab-paclitaxel resistance in breast cancer by promoting miR199a-5p maturation to inhibit Caveolin 1 translation;2023-05-03
5. Unchartered waters: Significance of fall in Ki67 index after short-term preoperative endocrine therapy in early breast cancers;Breast Disease;2023-02-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3